Back to top
more

Celgene Corporation (CELG)

(Delayed Data from NSDQ)

$95.42 USD

95.42
4,065,882

-0.09 (-0.09%)

Updated May 17, 2019 03:57 PM ET

Add to portfolio

2-Buy   2      

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
25.08%
18.07%
9.73%
5.25%
2.19%
10.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

B Value | C Growth | F Momentum | C VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Celgene Gets EC Nod for Label Expansion of Revlimid, Imnovid

Celgene (CELG) obtains approval for the label expansion of oncology drugs Revlimid and Imnovid in Europe.

RHHBY BMY BIIB CELG

Zacks Equity Research

Agios' Tibsovo Meets Endpoint in Cholangiocarcinoma Study

Agios' (AGIO) Tibsovo achieves the primary goal in a late-stage development that examined it for the previously treated IDH1 mutant cholangiocarcinoma. Shares rise in after-hours trading.

AGIO GILD CELG MRUS

Zacks Equity Research

4 High Earnings Yield Stocks to Strengthen Your Portfolio

Earnings yield is very effective for figuring out undervalued stocks.

KOP TEX CELG BHF

Zacks Equity Research

Biotech Stock Roundup: FDA Nod for REGN's Eylea in DR, Tie-Ups & Other Updates

Key highlights of the past week are regulatory and pipeline updates by the leading biotech companies.

CELG REGN GILD MYOV

Zacks Equity Research

CELG vs. VRTX: Which Stock Should Value Investors Buy Now?

CELG vs. VRTX: Which Stock Is the Better Value Option?

CELG VRTX

Zacks Equity Research

Prothena's (PRTA) Q1 Earnings Beat Estimates, Revenues Miss

Prothena's (PRTA) Q1 loss was narrower than expected, while revenues missed expectations.

RHHBY BMY CELG PRTA

Zacks Equity Research

bluebird's (BLUE) Loss Wider Than Expected, Revenues Down Y/Y

bluebird (BLUE) reports wider-than-expected Q1 loss. Nevertheless, the pipeline progress looks encouraging.

BLUE CELG REGN

Zacks Equity Research

The Zacks Analyst Blog Highlights: Apple, Microsoft, General Electric, Ecolab and Celgene

The Zacks Analyst Blog Highlights: Apple, Microsoft, General Electric, Ecolab and Celgene

ECL AAPL MSFT GE CELG

Zacks Equity Research

Agios (AGIO) Earnings and Revenues Surpass Estimates in Q1

Agios (AGIO) benefits from earnings as well as revenue beat in first-quarter 2019. However, Tibsovo sales fall sequentially, pulling the stock down.

AGIO PDLI CELG MRUS

Zacks Equity Research

The Zacks Analyst Blog Highlights: Biogen, Celgene, Incyte, Alexion and Vertex

The Zacks Analyst Blog Highlights: Biogen, Celgene, Incyte, Alexion and Vertex

VRTX BIIB CELG ALXN INCY

Mark Vickery

Top Analyst Reports for Apple, Microsoft & General Electric

Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Microsoft (MSFT) and General Electric (GE).

TRV MSFT GE ECL CELG AAPL

Zacks Equity Research

Biotech Stock Roundup: BIIB, VRTX, ALXN Q1 Earnings Top & Other Pipeline Updates

Key highlights of the past week are earnings releases by most leading biotech entities.

VRTX INCY CELG BIIB REGN ALXN AMGN

Zacks Equity Research

Is Celgene (CELG) Outperforming Other Medical Stocks This Year?

Is (CELG) Outperforming Other Medical Stocks This Year?

CELG

Zacks Equity Research

All You Need to Know About Celgene (CELG) Rating Upgrade to Buy

Celgene (CELG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

CELG

Zacks Equity Research

Celgene (CELG) Q1 Earnings Beat Estimates on Revlimid Sales

Celgene (CELG) beats on earnings and sales in the first quarter of 2019.

RHHBY BMY CELG XLRN

Zacks Equity Research

Bristol-Myers Q1 Earnings Beat, Sales Up on Strong Eliquis

Bristol-Myers (BMY) Q1 earnings and sales beat estimates on strong performance of Eliquis and Opdivo.

PFE BMY MRK CELG

Zacks Equity Research

Is a Beat in Store for Editas (EDIT) This Earnings Season?

On Editas' (EDIT) first-quarter earnings call, investor focus will be on the company's progress with its most advanced pipeline candidate, EDIT-101.

AGN CELG EDIT ADRO

Zacks Equity Research

The Zacks Analyst Blog Highlights: Celgene, Schlumberger, Becton, Dickinson, Twitter and PPG Industries

The Zacks Analyst Blog Highlights: Celgene, Schlumberger, Becton, Dickinson, Twitter and PPG Industries

TWTR PPG CELG BDX SLB

Mark Vickery

Top Analyst Reports for Celgene, Schlumberger & Becton, Dickinson

Today's Research Daily features new research reports on 16 major stocks, including Celgene (CELG), Schlumberger (SLB) and Becton, Dickinson (BDX).

TWTR SLB PPG ISRG CELG BDX

Zacks Equity Research

Celgene (CELG) Gains But Lags Market: What You Should Know

Celgene (CELG) closed the most recent trading day at $93.67, moving +0.27% from the previous trading session.

CELG

Zacks Equity Research

What's in Store for Celgene Corporation (CELG) Q1 Earnings?

Investors are looking forward to Revlimid's performance and updates on the impending acquisition agreement with Bristol-Myers, when Celgene Corporation (CELG) reports Q1 results.

GSK BMY BIIB CELG

Zacks Equity Research

Will Bristol-Myers (BMY) Disappoint This Earnings Season?

Performance of Opdivo and the impending acquisition of Celgene Corporation will be key areas of focus for the investors, when Bristol-Myers (BMY) reports first-quarter results.

BMY GSK BIIB CELG

Zacks Equity Research

Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal

Key highlights of the past week are collaborations and pipeline updates.

NVO BMY GILD CELG AXSM FCSC VRTX

Zacks Equity Research

Celgene (CELG) Gains As Market Dips: What You Should Know

Celgene (CELG) closed at $95.10 in the latest trading session, marking a +1.02% move from the prior day.

CELG